Precision Biologics
  • Home
  • Company
    • About Us
    • Contact Us
    • Board
    • Leadership
  • Clinical
    • Pipeline
    • Companion Diagnostics
    • Therapeutics
    • Clinical Trials
  • Science
    • Publications
      • Recent
      • Historical
    • Abstracts
    • Posters
    • Presentations
  • News and Events
Search
  • Home
  • Company
    • About Us
    • Contact Us
    • Board
    • Leadership
  • Clinical
    • Pipeline
    • Companion Diagnostics
    • Therapeutics
    • Clinical Trials
  • Science
    • Publications
      • Recent
      • Historical
    • Abstracts
    • Posters
    • Presentations
  • News and Events
  • Home
  • News and Events
  • Blog

Blog

11NovNovember 11, 2021

Precision Biologics to Deliver two Poster Presentations on our Clinical and Scientific Programs at the Society for Immunotherapy of Cancer (SITC) 36th Annual Meeting at the Walter E Washington Convention Center, Washington DC Nov 12-13, 2021

Strattmont Group2021-11-09T10:20:14-05:00

November 12th: poster number 883 (12:40–2:10 p.m. and 7–8:30 p.m.) Title: An anti-carcinoma monoclonal antibody (mAb)...

Facebook Twitter LinkedIn
Read more...
25FebFebruary 25, 2020

In Memoriam: Dr. Ariel Hollinshead

Strattmont Group2020-03-30T16:34:12-04:00

Ariel Cahill Hollinshead Hyun, PhD, a pioneering cancer researcher whose work contributed to the foundation...

Facebook Twitter LinkedIn
Read more...
17DecDecember 17, 2019

Rationale, discovery and clinical development of NEO-201

Strattmont Group2020-01-07T10:19:05-05:00

Most monoclonal antibody cancer therapies are developed for known targets and are commercially approved for...

Facebook Twitter LinkedIn
Read more...

Featured News

Precision Biologics, Inc. and National Cancer Institute Collaborators Deliver Poster Presentation at the ASCO Annual Meeting June 5, 2022
June 5, 2022
Dr. Philip M. Arlen provides perspective on the role of biomarkers for cancer immunotherapy at Oxford Global’s 2021 Biomarkers UK Conference
April 7, 2022
Precision Biologics, Inc. Announces Issuance of U.S. Patent: “MONOCLONAL ANTIBODY NEO-201 FOR THE TREATMENT OF HUMAN CARCINOMAS”
March 22, 2022
Want To Find Out More?

CONTACT INFO

301-500-8646

4814 Del Ray Avenue
Bethesda, MD 20814

COMPANY

Board
About Us
Contact Us
News and Events

CLINICAL

Pipeline
Diagnostics
Therapeutics
Clinical Trials

SCIENCE

Recent Publications
Publications – Historical
Abstracts
Posters
Presentations

© Copyright 2019-2021. Precision Biologics. All Rights Reserved.
Website Development By Strattmont Group